New Classification Criteria Developed For Scleroderma PDF Print E-mail
Monday, 07 October 2013 09:37
The 2013 Classification Criteria for Systemic Sclerosis have been developed and validated by the American College of Rheumatology and EULAR and should allow patients to be identified and treated earlier, according to the professional bodies.

Published in Arthritis and Rheumatism, the new criteria will classify patients as having Systemic Sclerosis if they have thickening of the skin in the middle part of the fingers (from the proximal to the metacarpophalangeal joints) regardless of other features.

A further seven features need to be assessed to make a Scleroderma classification if this criterion is not met. These features include skin thickening of the fingers, fingertip lesions, telangiectasia, abnormal nailfold capillaries, pulmonary arterial hypertension and interstitial lung disease, Raynaud’s phenomenon and Systemic Sclerosis-related antibodies.

However, several items that are useful for recognising Systemic Sclerosis in clinical practice, such as Calcinosis, flexion contractures of the fingers, tendon or bursal friction rubs, oesophageal dilatation and dysphagia were not included in the criteria because they did not improve sensitivity or specificity.

According to the authors of the new classification system, the 1980 ACR criteria for systemic sclerosis were updated by clustering items and simplifying the weighting of the different criteria. “The 1980 ACR criteria were not sensitive enough to identify patients with early disease or limited cutaneous System Sclerosis,” said co-author Dr Frank van den Hoogen from the Netherlands.

When validated  by comparing with non-scleroderma control cases, the new criteria proved to have a sensitivity of 0.91 and specificity of 0.92, whereas the old ACR criteria had a sensitivity and specificity of 0.75 and 0.72 respectively. “The new classification criteria should correctly classify more patients with the disease,” said co-author Dr Janet Pope from Ontario.

“Criteria that are more specific will allow for earlier identification and better treatment for those with systemic sclerosis,” she said. The authors acknowledged that testing and validating the new criteria was difficult because there is no ‘gold standard’ to define a standard case of Systemic Sclerosis.  The ACR-EULAR committee therefore had to rely on a consensus of expert opinion, with a focus on controversial cases.

“the ACR/EULAR classification criteria for systemic sclerosis perform better than the 1980 ACR preliminary criteria in terms of both sensitivity and specificity,” the authors conclude. They are relatively simple to apply in individual subjects [and] may be endorsed as inclusion criteria for systemic sclerosis studies,” they added

Source: Rheumatology Update (2013)
 
More articles :

» Collagen Vascular Disease

Connective tissue is a major tissue in our body and is responsible for forming the structure of the body parts. It can be considered as a tissue that forms the framework or matrix of the body. It is made up of two proteins, collagen and elastin....

» Real-World Bosentan Therapy Successful in Pulmonary Arterial Hypertension: Presented at ATS

Real-life experiences in treating patients with pulmonary arterial hypertension with bosentan appears to provide similar efficacy as seen in clinical trials -- despite patients being somewhat older and having more scleroderma, researchers said today...

» Endothelin Drugs Benefit Those With Pulmonary Hypertension

Breaking news from has reported that recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of and provides hope for treating other chronic...

» New Research Findings May Bring Breakthrough For Scleroderma Patients

Research presented at the European Academy of Dermatology and Venereology in Prague, Czech Republic, suggests that inhibition of the may be a viable therapeutic target in patients.This finding builds on previous research by presenter and lead...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials

Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...

» Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease

Tamiko R. Katsumoto, Shelia M. Violette, and Dean SheppardReceived 27 May 2011; Accepted 15 August 2011Interstitial lung disease (ILD) is a commonly encountered complication of systemic sclerosis (SSc) and accounts for a significant proportion of...

Comments  

 
+1 #2 adelwyn 2013-10-08 07:02
Good Morning Robyn, we would like to thank you and your team for the comment and continued support. We will continue to do what we can, for all Scleroderma patients around the world.
Report to administrator
 
 
+2 #1 Robyn Sims 2013-10-08 02:22
We wish to thank you for your well resourced information. Scleroderma Australia appreciates being able to share your articles with our members.
Well Done.
Robyn Sims
President
Scleroderma Australia
Report to administrator